Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

Access to begin phase II trial of OraRinse for treatment and prevention of mucositis

Jan. 31, 2000

NYU School of Medicine and P&U establish anticancer drug discovery collaboration

Jan. 31, 2000

Oxford BioMedica and IDM to collaborate on cell-based therapies

Jan. 31, 2000

Two new anticancer human MAbs enter development at AVI BioPharma

Jan. 28, 2000

Schering-Plough seeks E.U. approval of Caelyx for treatment of advanced ovarian cancer

Jan. 28, 2000

Licensing opportunity from NIH: 5-lipoxygenase inhibitors as anticancer agents

Jan. 28, 2000

Novel CDK4 inhibitor series available for licensing from NIH

Jan. 27, 2000

Dendreon initiates patient enrollment in phase III prostate cancer study

Jan. 27, 2000

Eisai team identifies promising new selective RARalpha agonist

Jan. 27, 2000

Enzon describes pegylated prodrugs of antitumor compounds with increased water solubility

Jan. 27, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 13, 2026.
AAIC 2026: Age of amyloid is being joined by time of tau
BioWorld
The Alzheimer’s Association International Conference (AAIC) is the world’s biggest dementia conference. And at the AAIC 2026 meeting, there is big buzz around...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
NRF2 activators reported in Vailima Peninsula patent
BioWorld Science
Vailima Peninsula Pty Ltd. has discovered new nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators potentially useful for the treatment of...
News in brief
BioWorld Asia
BioWorld Asia briefs for July 14, 2026